Warino Lindsey, Libecco James
Northeastern Ohio Universities College of Medicine, Rootstown, USA.
J Drugs Dermatol. 2006 Mar;5(3):273-4.
Cancer is a major cause of death in immunosuppressed transplant patients. Therefore, sirolimus is frequently used in these patients for its immunosuppressive and antineoplastic properties. However, a variety of cutaneous side effects have resulted from sirolimus therapy. Consequently, dermatologists must be aware of such adverse events and understand the risks and benefits of discontinuing therapy.